Avacta Group (LON:AVCT) Trading Up 15.5% - Here's Why

Key Points

• Shares jumped 15.5% on Thursday to as high as GBX 82.74, with about 7.01 million shares traded—roughly a 257% increase versus average volume.
• Financials are mixed: market cap £367.34m and a negative P/E (-4.62) alongside a high quick ratio (4.96) but an extremely elevated debt-to-equity (14,168.75) and a low current ratio (0.79).
• Company focus: Avacta is a clinical‑stage biopharma developing a tumor‑activated "pre|CISION" platform that releases potent therapeutics at tumors by targeting fibroblast activation protein (FAP).

Avacta Group Plc (LON:AVCT - ) shares were up 15.5% on Thursday . The company traded as high as GBX 82.74 and last traded at GBX 82. Approximately 7,010,121 shares traded hands during trading, an increase of 257% from the average daily volume of 1,962,845 shares. The stock had previously closed at GBX 71.

Avacta Group Stock Up 14.1%

The company has a quick ratio of 4.96, a current ratio of 0.79 and a debt-to-equity ratio of 14,168.75. The business's 50-day moving average is GBX 69.33 and its two-hundred day moving average is GBX 66.75. The stock has a market capitalization of £367.34 million, a price-to-earnings ratio of -4.62 and a beta of 1.12.

Avacta Group Company Profile

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics. The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US. Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.